Expert Systems proudly celebrates the promising clinical results of oral once-daily lonitoclax, a next-generation BCL-2 inhibitor developed in collaboration with Lomond Therapeutics.

Expert Systems announces a major milestone in its partnership with Lomond Therapeutics. The U.S. Food and Drug Administration (FDA) has granted clearance for Lomond's Investigational New Drug (IND) application for a Phase 1 clinical study of lonitoclax, a selective BCL-2 inhibitor, in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and select low-grade lymphomas.

Expert Systems celebrates a key milestone in the development of tivoxavir marboxil, a potential best-in-class inhibitor of the highly-conserved influenza protein, CAP-dependent endonuclease (CEN), intended for use across a broad range of flu viruses.

Expert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the development of ratutrelvir, a SARS-CoV-2 Main protease (Mpro) inhibitor.

 Expert Systems is expanding its operations in Europe through a strategic collaboration with Polku Therapeutics Oy, a new Helsinki-based startup focused on developing treatments for neurodegenerative diseases.

Expert Systems, announces a significant milestone in partnership with Eilean Therapeutics LLC: the start of Phase 1 trial of balamenib (ZE63-0302), a highly selective inhibitor of the menin–KMT2A binding interaction, under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutics Goods Administration (TGA).

Expert Systems announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program.

Expert Systems announces a significant milestone in partnership with Eilean Therapeutics LLC: the successful completion of a single ascending dose Phase 1 clinical trial for lomonitinib, a selective pan-FLT3/IRAK4 inhibitor, alongside the launch of a multiple ascending dose Phase 1 study.

Expert Systems proudly announces a significant achievement in collaboration with Eilean Therapeutics LLC: the commencement of first-in-human trials for eiletoclax, a highly potent BCL2 inhibitor, within just three years.

Expert Systems Inc. announces the initiation of a first-in-human trial of TRX01 by their partner Trawsfynydd Therapeutics.